VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Breast Oncology Program at the University of Michigan Cancer Center Ann Arbor. After his talk on the utility of genetic signatures to select adjuvant treatment he discussed his findings and conclusions with Oncology Time reporter Sarah Maxwell.
You may also like...
Which patients for bisphosphonate control of breast cancer metastasis? 29 Mar, 2013 Lowering hematocrit below 45 per cent protects against clotting risk in patients with polycythemia vera — randomized study finding 11 Dec, 2012 Prostate Genomics—Which Patients Will Die? 20 Apr, 2017 Combination immunotherapy improved overall survival in patients with metastatic melanoma 15 Sep, 2013
- Previous story New Strategies for Preventing ER-Negative Breast Cancer
- Next story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014